Exact Mass: 415.3059478

Exact Mass Matches: 415.3059478

Found 31 metabolites which its exact mass value is equals to given mass value 415.3059478, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Myxalamid A

(2E,4E,6Z,8E,10E,12R,13R,14E)-13-hydroxy-N-[(1S)-2-hydroxy-1-methyl-ethyl]-2,10,12,14,16-pentamethyl-octadeca-2,4,6,8,10,14-hexaenamide

C26H41NO3 (415.3086276)


   

N-Stearoyl Methionine

N-Stearoyl-DL-methionine, monosodium salt, (L)-isomer

C23H45NO3S (415.311998)


N-stearoyl methionine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Methionine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl Methionine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl Methionine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Eicosapentaenoyl Isoleucine

2-(icosa-5,8,11,14,17-pentaenamido)-3-methylpentanoic acid

C26H41NO3 (415.3086276)


N-eicosapentaenoyl isoleucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Isoleucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Isoleucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Isoleucine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Eicosapentaenoyl Leucine

2-(icosa-5,8,11,14,17-pentaenamido)-4-methylpentanoic acid

C26H41NO3 (415.3086276)


N-eicosapentaenoyl leucine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Leucine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Leucine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Leucine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   
   

(Z,Z)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-octadeca-9,12-dienamide|Livanil|N-vanillyl-9Z,12Z-octadecadienamide|N-vanillyllinoleamide

(Z,Z)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-octadeca-9,12-dienamide|Livanil|N-vanillyl-9Z,12Z-octadecadienamide|N-vanillyllinoleamide

C26H41NO3 (415.3086276)


   
   

NA 26:6;O2

N-(9Z,12Z-octadecadienoyl) dopamine

C26H41NO3 (415.3086276)


   

N-(1-Oxooctadecyl)-DL-methionine

N-(1-Oxooctadecyl)-DL-methionine

C23H45NO3S (415.311998)


   

N-Linoleoyldopamine

N-Linoleoyldopamine

C26H41NO3 (415.3086276)


D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors

   

N-Eicosapentaenoyl Leucine

N-Eicosapentaenoyl Leucine

C26H41NO3 (415.3086276)


   

N-Eicosapentaenoyl Isoleucine

N-Eicosapentaenoyl Isoleucine

C26H41NO3 (415.3086276)


   

17-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]heptadecanoate

17-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]heptadecanoate

C23H43O6- (415.3059478)


   

(16R)-16-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyheptadecanoate

(16R)-16-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyheptadecanoate

C23H43O6- (415.3059478)


   

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

(3Z,6Z,9Z,12Z,15Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]octadeca-3,6,9,12,15-pentaenamide

C26H41NO3 (415.3086276)


   

(2E,4E,6Z,8E,10E,12R,13R,14E)-13-hydroxy-N-[(1S)-2-hydroxy-1-methyl-ethyl]-2,10,12,14,16-pentamethyl-octadeca-2,4,6,8,10,14-hexaenamide

(2E,4E,6Z,8E,10E,12R,13R,14E)-13-hydroxy-N-[(1S)-2-hydroxy-1-methyl-ethyl]-2,10,12,14,16-pentamethyl-octadeca-2,4,6,8,10,14-hexaenamide

C26H41NO3 (415.3086276)


   

oscr#30(1-)

oscr#30(1-)

C23H43O6 (415.3059478)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#30, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

ascr#30(1-)

ascr#30(1-)

C23H43O6 (415.3059478)


Conjugate base of ascr#30

   
   

NA-Dopamine 18:2(9E,12E)

NA-Dopamine 18:2(9E,12E)

C26H41NO3 (415.3086276)


   

NA-Dopamine 18:2(9Z,12Z)

NA-Dopamine 18:2(9Z,12Z)

C26H41NO3 (415.3086276)


   

NA-Ile 20:5(5Z,8Z,11Z,14Z,17Z)

NA-Ile 20:5(5Z,8Z,11Z,14Z,17Z)

C26H41NO3 (415.3086276)


   

NA-Leu 20:5(5Z,8Z,11Z,14Z,17Z)

NA-Leu 20:5(5Z,8Z,11Z,14Z,17Z)

C26H41NO3 (415.3086276)


   
   
   
   

(2e,4e,6z,8e,10e,12s,13r,14e,16r)-13-hydroxy-n-[(2r)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(2e,4e,6z,8e,10e,12s,13r,14e,16r)-13-hydroxy-n-[(2r)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C26H41NO3 (415.3086276)


   

(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(2e,4e,6z,8e,10e,12r,13r,14e,16s)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C26H41NO3 (415.3086276)


   

13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C26H41NO3 (415.3086276)


   

(2e,4e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(2e,4e)-13-hydroxy-n-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C26H41NO3 (415.3086276)


   

(2e,4e,6z,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

(2e,4e,6z,8e,10e,12r,13r,14e)-13-hydroxy-n-[(2s)-1-hydroxypropan-2-yl]-2,10,12,14,16-pentamethyloctadeca-2,4,6,8,10,14-hexaenimidic acid

C26H41NO3 (415.3086276)